⌘K
Loading ticker…
As of 2026-08-24, Allogene Therapeutics, Inc. Common Stock (ALLO) has a 3-month relative strength percentile of 51 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 58. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.4%, relative volume 0.79×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ALLO is in a stage 3 topping pattern, week 5. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 2.5% / 5.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
ALLO is held by 17 ETFs as of May 2026. Top owner: SCHA at 0.01% weight, $3M notional. Top 3 carry $6M.
Held by 34 ETFs · $57M across latest filings · largest weight 1.25% (WDNA).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $3M | — |
| VTWO | 0.01% | $2M | — |
| VHTVanguard Health Care ETF | 0.01% | $2M | — |
| VFMO | 0.06% | $1M | new |
| AVSC | 0.02% | $443K | new |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $325K | — |
| VTWV | 0.02% | $260K | — |
| QQQS | 0.32% | $60K | −0.58 pp |
| VTHRVanguard Russell 3000 ETF | 0.00% | $31K | — |
| IBBQ | 0.04% | $26K | — |
Showing 10 of 17 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALLO Jan avg: 12.80% median: 16.20% win: 75% σ: 21.38% n: 4 2022-04-12 → 2026-07-31 | ALLO Feb avg: 20.29% median: 23.91% win: 75% σ: 31.13% n: 4 2022-04-12 → 2026-07-31 | ALLO Mar avg: -17.13% median: -17.22% win: 0% σ: 7.76% n: 4 2022-04-12 → 2026-07-31 | ALLO Apr avg: -5.48% median: -1.42% win: 40% σ: 21.23% n: 5 2022-04-12 → 2026-07-31 | ALLO May avg: -9.25% median: -5.03% win: 20% σ: 12.47% n: 5 2022-04-12 → 2026-07-31 | ALLO Jun avg: 4.81% median: -4.15% win: 20% σ: 21.81% n: 5 2022-04-12 → 2026-07-31 | ALLO Jul avg: 7.81% median: 8.85% win: 60% σ: 13.63% n: 5 2022-04-12 → 2026-07-31 | ALLO Aug avg: -8.66% median: -9.34% win: 25% σ: 11.17% n: 4 2022-04-12 → 2026-07-31 (current) | ALLO Sep avg: -5.88% median: -6.02% win: 50% σ: 16.24% n: 4 2022-04-12 → 2026-07-31 | ALLO Oct avg: -6.11% median: -6.69% win: 0% σ: 4.86% n: 4 2022-04-12 → 2026-07-31 | ALLO Nov avg: -1.53% median: -3.60% win: 25% σ: 14.26% n: 4 2022-04-12 → 2026-07-31 | ALLO Dec avg: -4.97% median: -10.14% win: 25% σ: 30.49% n: 4 2022-04-12 → 2026-07-31 |